Status:
UNKNOWN
The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
CLL
Multiple Myeloma
Eligibility:
All Genders
18-100 years
Brief Summary
The corona pandemic is a continuing global challenge due to Corona Virus 2019 (COVID-19). The purpose of the study is to evaluate the capability of Haemato-oncology patients to generate antibodies ag...
Detailed Description
In December 2019, a backlog of patients with respiratory disease was identified in Hubei Province, China. The number of infections increased rapidly, and more patients were identified in other provinc...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Patient sex - male and female
- CLL, Lymphoma or Multiple Myeloma patients, in follow up or during an active treatment period, who have recovered from COVID19 (COVID19 recovery defined as the presence of two negative PCR tests), who have been vaccinated against the virus or patients who plan to be vaccinated against COVID19
- Healthy participants who have been vaccinated against the virus as a control group.
Exclusion
- Irrelevant
Key Trial Info
Start Date :
January 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 24 2022
Estimated Enrollment :
630 Patients enrolled
Trial Details
Trial ID
NCT04746092
Start Date
January 6 2021
End Date
May 24 2022
Last Update
August 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel, 6423906